A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression

AIDS

Volumn 23, Issue 14, 2009, Pages 1817-1828

  Tso, For Yue ^a   Hoffmann, Federico G ^a   Tully, Damien C ^a   Lemey, Philippe ^d   Rasmussen, Robert A ^b,c   Zhang, Hong ^a   Ruprecht, Ruth M ^b,c   Wood, Charles ^a  

^a UNIVERSITY OF NEBRASKA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Disease progression; Evolution; HIV 1; Rhesus macaque; Simian HIV

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLONE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; EVOLUTION; GENE SEQUENCE; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MACACA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYLOGENY; PRIORITY JOURNAL; RNA VIRUS; VIRUS ENVELOPE; VIRUS LOAD; ZAMBIA;

AMINO ACID SEQUENCE; ANIMALS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EVOLUTION, MOLECULAR; GENETIC VARIATION; GLYCOSYLATION; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MACACA MULATTA; MOLECULAR SEQUENCE DATA; PHYLOGENY; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRAL LOAD;

EID: 70249128728     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832f3da6     Document Type: Article

References (58)

1. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296:2354-2360.
2. Geyer H, Holschbach C, Hunsmann G, Schneider J. Carbohydrates of human immunodeficiency virus. Structures of oligo-saccharides linked to the envelope glycoprotein 120. J Biol Chem 1988; 263:11760-11767.
3. Sagar M, Wu X, Lee S, Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006; 80:9586-9598.
4. Saunders CJ, McCaffrey RA, Zharkikh I, Kraft Z, Malenbaum SE, Burke B, et al. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol 2005; 79:9069-9080.
5. Stevceva L, Yoon V, Anastasiades D, Poznansky MC. Immune responses to HIV Gp120 that facilitate viral escape. Curr HIV Res 2007; 5:47-54.
6. Thorner AR, Barouch DH. HIV-1 vaccine development: progress and prospects. Curr Infect Dis Rep 2007; 9:71-75.
7. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312.
8. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glyco-protein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665.
9. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191:666-677. (Pubitemid 40271053)
10. Greenier JL, Van Rompay KK, Montefiori D, Earl P, Moss B, Marthas ML. Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals. Virol J 2005; 2:11.
11. Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 2005; 79:771-779.
12. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671.
13. Xu R, Srivastava IK, Kuller L, Zarkikh I, Kraft Z, Fagrouch Z, et al. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Virology 2006; 349:276-289.
14. Rasmussen RA, Ong H, Song R, Chenine AL, Ayash-Rashkovsky M, Hu SL, et al. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. AIDS 2007; 21:1841-1848.
15. Hayami M, Igarashi T. SIV/HIV-1 chimeric viruses having HIV-1 env gene: a new animal model and a candidate for attenuated live vaccine. Leukemia 1997; 11 (Suppl 3):95-97.
16. Karlsson GB, Halloran M, Li J, Park IW, Gomila R, Reimann KA, et al. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4R lymphocyte depletion in rhesus monkeys. J Virol 1997; 71:4218-4225.
17. Luciw PA, Pratt-Lowe E, Shaw KE, Levy JA, Cheng-Mayer C. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci U S A 1995; 92:7490-7494.
18. Reimann KA, Li JT, Voss G, Lekutis C, Tenner-Racz K, Racz P, et al. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol 1996; 70:3198-3206.
19. Shibata R, Maldarelli F, Siemon C, Matano T, Parta M, Miller G, et al. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J Infect Dis 1997; 176:362-373.
20. Vlasak J, Ruprecht RM. AIDS vaccine development and challenge viruses: getting real. AIDS 2006; 20:2135-2140.
21. Blay WM, Gnanakaran S, Foley B, Doria-Rose NA, Korber BT, Haigwood NL. Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques. J Virol 2006; 80: 999-1014.
22. Hofmann-Lehmann R, Vlasak J, Chenine AL, Li PL, Baba TW, Montefiori DC, et al. Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage. J Virol 2002; 76:5278-5284.
23. Kraft Z, Derby NR, McCaffrey RA, Niec R, Blay WM, Haigwood NL, et al. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J Virol 2007; 81:6402-6411.
24. BeaumontT, van NuenenA, Broersen S, Blattner WA, Lukashov VV, Schuitemaker H. Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J Virol 2001; 75:2246-2252.
25. Choisy M, Woelk CH, Guegan JF, Robertson DL. Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes. J Virol 2004; 78:1962-1970.
26. Korber BT, MacInnes K, Smith RF, Myers G. Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol 1994; 68:6730-6744.
27. Zhang H, Hoffmann F, He J, He X, Kankasa C, Ruprecht R, et al. Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant. Retrovirology 2005; 2:67.
28. Humbert M, Rasmussen RA, SongR, OngH, Sharma P, Chenine AL, et al. SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retro-virology 2008; 5:94.
29. Song RJ, Chenine AL, Rasmussen RA, Ruprecht CR, Mirshahidi S, Grisson RD, et al. Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol 2006; 80:8729-8738.
30. Hofmann-Lehmann R, Swenerton RK, Liska V, Leutenegger CM, Lutz H, McClure HM, Ruprecht RM. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one-versus two-enzyme systems. AIDS Res Hum Retroviruses 2000; 16:1247-1257.
31. Zhang H, Hoffmann F, He J, He X, Kankasa C, West JT, et al. Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology 2006; 3:73.
32. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-4680.
33. Kosakovsky Pond SL, Frost SD. Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol Biol Evol 2005; 22:1208-1222.
34. Grenfell BT, Pybus OG, Gog JR, Wood JL, Daly JM, Mumford JA, Holmes EC. Unifying the epidemiological and evolutionary dynamics of pathogens. Science 2004; 303:327-332.
35. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999; 73:10489-10502.
36. Ross HA, Rodrigo AG. Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. J Virol 2002; 76:11715-11720.
37. Williamson S. Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression. Mol Biol Evol 2003; 20:1318-1325.
38. Markham RB, Wang WC, Weisstein AE, Wang Z, Munoz A, Templeton A, et al. Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci U S A 1998; 95:12568-12573.
39. Salvatori F, Masiero S, Giaquinto C, Wade CM, Brown AJ, Chieco-Bianchi L, De Rossi A. Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease. J Virol 1997; 71:4694-4706.
40. Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, Krizan RW, et al. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 2005; 79:9006-9018.
41. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, Abdool Karim SS, et al. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 2008; 82: 1860-1869.
42. Morrison HG, Kirchhoff F, Desrosiers RC. Effects of mutations in constant regions 3 and 4 of envelope of simian immunodeficiency virus. Virology 1995; 210:448-455.
43. Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J, Sfakianos JN, et al. Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to auto-logous neutralization of subtype C human immunodeficiency virus type 1. J Virol 2007; 81:5658-5668.
44. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002; 76:7293-7305.
45. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, et al. The broadly neutralizing antihu-man immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 2002; 76:7306-7321.
46. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, Korber B. Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J Virol 2007; 81:4886-4891.
47. Buckley KA, Li PL, Khimani AH, Hofmann-Lehmann R, Liska V, Anderson DC, et al. Convergent evolution of SIV env after independent inoculation of rhesus macaques with infectious proviral DNA. Virology 2003; 312:470-480.
48. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005; 79: 6528-6531.
49. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004; 303:2019-2022.
50. Haggerty S, Dempsey MP, Bukrinsky MI, Guo L, Stevenson M. Posttranslational modifications within the HIV-1 envelope glycoprotein which restrict virus assembly and CD4-dependent infection. AIDS Res Hum Retroviruses 1991; 7:501-510.
51. Ohgimoto S, Shioda T, Mori K, Nakayama EE, Hu H, Nagai Y. Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity. J Virol 1998; 72:8365-8370.
52. Willey RL, Smith DH, Lasky LA, Theodore TS, Earl PL, Moss B, et al. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol 1988; 62:139-147.
53. Wu Z,Kayman SC, Honnen W, ReveszK, Chen H, Vijh-Warrier S, et al. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J Virol 1995; 69:2271-2278.
54. Luciw PA, Mandell CP, Himathongkham S, Li J, Low TA, Schmidt KA, et al. Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques. Virology 1999; 263:112-127.
55. Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, et al. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 2008; 82:638-651.
56. Fung MS, Sun CR, Gordon WL, Liou RS, Chang TW, Sun WN, et al. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol 1992; 66:848-856.
57. Sullivan N, Thali M, Furman C, Ho DD, Sodroski J. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J Virol 1993; 67:3674-3679.
58. McCaffrey RA, Saunders C, Hensel M, Stamatatos L. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by antigp120 and antigp41 antibodies. J Virol 2004; 78:3279-3295.